Video

Part 2: Practical Considerations For Venetoclax in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP

Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.

Related Videos
Related Content
HOPA 2025: Matthew Lei, PharmD, BCOP, Shares Critical Themes and Hot Topic Sessions
April 9th 2025

HOPA 2025: Matthew Lei, PharmD, BCOP, Shares Critical Themes and Hot Topic Sessions

Matthew M. Lei, PharmD, BCOP Alana Hippensteele, Lead Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Depiction of anemia, reduced red blood cells in bloodstream | Image Credit: © Prime Stox - stock.adobe.com
April 4th 2025

MANIFEST-2 Study: Pelabresib Plus Ruxolitinib Is Superior to JAK Inhibitors Alone

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Chemical structure of MDM2 protein binding p53 | Image Credit: © Juan Gärtner - stock.adobe.com
April 3rd 2025

Siremadlin Demonstrates Efficacy, Safety in Treatment of Patients With TP53 Wild-Type Chronic Lymphocytic Leukemia

Alexandra Gerlach, Associate Editor
Visualization of a CAR T-cell | Image Credit: © DruZhi Art - stock.adobe.com
April 3rd 2025

Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma

Alexandra Gerlach, Associate Editor